SCHEMBL3175111

SCHEMBL3175111

CS(=O)(=O)c1nc(N)cc(N2CCOCC2)n1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPT P10636 1/20 0.47
MTOR P42345 4/20 0.46
ATR Q13535 3/20 0.43
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CA P42336 4/20 0.41
AKT1 P31749 1/20 0.41
PIK3C3 Q8NEB9 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1029670 0.82 MAPT (0.57) CRHBPCRHR2KMT2AMEN1POLB
SCHEMBL21143710 0.78 L3MBTL1 (0.42) CRHBPCRHR2KMT2AMEN1POLB
SCHEMBL794010 0.76 CRHBP (0.61) CRHBPCRHR2KMT2AMEN1POLB
SCHEMBL20153235 0.76 ADORA2A (0.50) KMT2AMEN1MAPTMTORRAF1
SCHEMBL19708837 0.76 SMN1; SMN2 (0.62) CRHBPCRHR2KMT2AMAPTHRH4
SCHEMBL3231344 0.76 CRHBP (0.70) CRHBPCRHR2KMT2AMEN1POLB
SCHEMBL19805807 0.76 NPC1 (0.54) KMT2AMEN1MAPTMTORATR
SCHEMBL29976085 0.76 NPC1 (0.54) KMT2AMEN1MAPTMTORATR
SCHEMBL3289509 0.74 KMT2A (0.65) CRHBPCRHR2KMT2AMEN1POLB
SCHEMBL2205962 0.73 AURKA (0.44) CRHBPCRHR2KMT2APIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2010-01-14 US disclosed
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2010-01-14 US disclosed
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2010-01-14 US disclosed
EP-2032138-A2 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK Merck Sharp & Dohme Limited (GB) 2009-03-11 EP disclosed
WO-2007141571-A2 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2007-12-13 WO disclosed
WO-2007141571-A2 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MAPT, MARK4, MARK3 CRHBP 3034/4885CRHR2 4300/4885KMT2A 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.